Indegene Unveils NEXT Tool to Automate Medical Writing with GenAI

16 Jul 2025 CW Team

Medical writing teams are under constant pressure to deliver precise, regulatory-ready documents within tight timelines, often while navigating fragmented data and evolving compliance needs. NEXT Medical Writing Automation addresses these challenges head-on. It combines Indegene’s decades of domain knowledge with the power of its AI engine, Cortex. As a life sciences-specialist knowledge engineering and multi-agent orchestration platform, Cortex by Indegene enables life sciences leaders to adopt and scale this transformative technology with enterprise-grade governance.

Purpose-built by experienced medical writers, NEXT Medical Writing Automation operates within familiar environments like Microsoft Word, auto-generating compliant drafts that adapt to diverse sponsor formats and workflows. It integrates seamlessly with Regulatory Information Management (RIM) systems, maintaining traceability and consistency across documents.

With automated scheduling, intelligent task assignments, and robust data flow integration, NEXT Medical Writing Automation helps life sciences organizations scale operations efficiently while maintaining a strong compliance backbone. As document requirements grow and scrutiny intensifies, such solutions become essential to sustaining operational excellence. “We see this platform as more than automation—it’s about elevating the entire practice of medical writing,” said Sameer Lal, SVP, Enterprise Medical Solutions, Indegene. “Writers can now focus on strategic tasks and critical thinking, while the platform manages the heavy lift of data and formatting.”

The launch of NEXT Medical Writing Automation reinforces Indegene’s commitment to building AI-driven, domain-first solutions that help life sciences organizations modernize critical processes and meet business objectives with confidence.

Indegene, a digital-first, life sciences commercialization company, today announced the launch of NEXT Medical Writing Automation, an advanced platform that combines deep medical writing expertise with generative AI (GenAI) to accelerate the creation of high-quality, compliant documents across clinical development, regulatory submissions, and beyond.Medical writing teams are under constant pressure to deliver precise, regulatory-ready documents within tight timelines, often while navigating fragmented data and evolving compliance needs. NEXT Medical Writing Automation addresses these challenges head-on. It combines Indegene’s decades of domain knowledge with the power of its AI engine, Cortex. As a life sciences-specialist knowledge engineering and multi-agent orchestration platform, Cortex by Indegene enables life sciences leaders to adopt and scale this transformative technology with enterprise-grade governance.Purpose-built by experienced medical writers, NEXT Medical Writing Automation operates within familiar environments like Microsoft Word, auto-generating compliant drafts that adapt to diverse sponsor formats and workflows. It integrates seamlessly with Regulatory Information Management (RIM) systems, maintaining traceability and consistency across documents.With automated scheduling, intelligent task assignments, and robust data flow integration, NEXT Medical Writing Automation helps life sciences organizations scale operations efficiently while maintaining a strong compliance backbone. As document requirements grow and scrutiny intensifies, such solutions become essential to sustaining operational excellence. “We see this platform as more than automation—it’s about elevating the entire practice of medical writing,” said Sameer Lal, SVP, Enterprise Medical Solutions, Indegene. “Writers can now focus on strategic tasks and critical thinking, while the platform manages the heavy lift of data and formatting.”The launch of NEXT Medical Writing Automation reinforces Indegene’s commitment to building AI-driven, domain-first solutions that help life sciences organizations modernize critical processes and meet business objectives with confidence.

Infrastructure Transport

06 Feb 2026

Lucknow Metro East-West Corridor Consultancy Contract Awarded

The Uttar Pradesh Metro Rail Corporation has awarded the first construction-related consultancy contract for the Lucknow Metro East West Corridor to a joint venture of AYESA Ingenieria Arquitectura SAU and AYESA India Pvt Ltd. The firm was declared the lowest bidder for the Detailed Design Consultant contract for Lucknow Metro Line-2 under Phase 1B and the contract was recommended following the financial bid. The contract is valued at Rs 159.0 million (mn), covering design services for the corridor. Lucknow Metro Line-2 envisages the construction of an 11.165 kilometre corridor connecting Cha..

Infrastructure Urban

06 Feb 2026

Div Com Kashmir Urges Fast Tracking Of Jhelum Water Transport Project

The Divisional Commissioner of Kashmir has called for the fast-tracking of the Jhelum water transport project, urging district administrations and relevant agencies to accelerate planning and clearances. In a meeting convened at the divisional headquarters, the commissioner instructed officials from irrigation, public health engineering and municipal departments to prioritise the project and coordinate survey and design work. The directive emphasised removal of administrative bottlenecks and close monitoring to ensure timely mobilisation of resources and contractors. Officials were told to in..

Infrastructure Urban

06 Feb 2026

Interarch Reports Strong Q3 And Nine Month Results

Interarch Building Solutions Limited reported unaudited results for the third quarter and nine months ended 31 December 2025, recording strong revenue growth driven by execution and a robust order book. Net revenue for the third quarter rose by 43.7 per cent to Rs 5.225 billion (bn), compared with Rs 3.636 bn a year earlier, reflecting heightened demand in pre-engineered building projects. The company’s total order book as at 31 January 2026 stood at Rs 16.85 bn, supporting near-term visibility. EBITDA excluding other income for the quarter increased by 43.2 per cent to Rs 503 million (mn),..